SILVERARC CAPITAL MANAGEMENT, LLC — 13F Holdings & Portfolio
CIK 1816307 · latest 13F-HR filed 2026-11-12
SILVERARC CAPITAL MANAGEMENT, LLC manages $854.4M in 13F-reported U.S. long-equity assets across 70 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are KOD (8.32%), CELC (7.48%), COGT (5.90%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 15 new positions and exited 17; 13 existing positions rose in reported value and 28 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-12
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
5 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 54.2%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 30, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| BRAUER, PAUL, NMN Control | CHIEF COMPLIANCE OFFICER since Feb 2025 | Less than 5% | Individual |
| GANDHI, DEVESH, SHARAD Control | FOUNDER & CHIEF EXECUTIVE OFFICER since Apr 2019 | 75% or more | Individual |
| GOODELL, AMANDA, LYNN Control | CHIEF FINANCIAL OFFICER since Apr 2024 | Less than 5% | Individual |
| TIMPSON, ANDREW, JOSEPH Control | PRESIDENT & CHIEF OPERATING OFFICER since Jul 2019 | Less than 5% | Individual |
Ownership & leadership changes · 3 filings with changes since May 24, 2019
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedGANDHI, DEVESH, SHARAD · title FOUNDER & PRESIDENT → FOUNDER & CHIEF EXECUTIVE OFFICER
- ChangedTIMPSON, ANDREW, JOSEPH · title CHIEF OPERATING OFFICER → PRESIDENT & CHIEF OPERATING OFFICER
- AddedBRAUER, PAUL, NMN · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- AddedGOODELL, AMANDA, LYNN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ChangedTIMPSON, ANDREW, JOSEPH · title CHIEF OPERATING OFFICER & CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER
- AddedTIMPSON, ANDREW, JOSEPH · CHIEF OPERATING OFFICER & CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedGANDHI, DEVESH, SHARAD · title FOUNDER, PRESIDENT, CHIEF COMPLIANCE OFFICER → FOUNDER & PRESIDENT
- ListedGANDHI, DEVESH, SHARAD · FOUNDER, PRESIDENT, CHIEF COMPLIANCE OFFICER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- KODIAK SCIENCES INC$49.8M +234.2%
- BIOGEN INC$15.1M +145.1%
- SAGIMET BIOSCIENCES INC$14.4M +63.5%
- CELCUITY INC$11.5M +21.9%
- MONTE ROSA THERAPEUTICS INC$10.3M +38.5%
Top Trims
- SYNDAX PHARMACEUTICALS INC-$21.9M -82.5%
- ASCENDIS PHARMA A/S-$20.3M -37.0%
- ENLIVEN THERAPEUTICS INC-$19.3M -77.6%
- DIANTHUS THERAPEUTICS INC-$17.2M -45.2%
- PRAXIS PRECISION MEDICINES I-$16.2M -73.8%
New Positions
- CELLDEX THERAPEUTICS INC NEW$15.8M
- RAINIER ACQUISITION CORP$8.7M
- YARROW BIOSCIENCE INC$6.8M
- ARCTURUS THERAPEUTICS HLDGS$6.3M
- KINIKSA PHARMACEUTICALS INTL$5.6M
Exited Positions
- VERACYTE INC$18.7M
- GUARDANT HEALTH INC$15.0M
- TREVI THERAPEUTICS INC$12.6M
- VERADERMICS INC$11.7M
- XENON PHARMACEUTICALS INC$11.3M
SILVERARC CAPITAL MANAGEMENT, LLC Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | KODIAK SCIENCES INC | KOD | 50015M109 | $71.1M | 8.32% | 750,170 | SH |
| 2 | CELCUITY INC | CELC | 15102K100 | $63.9M | 7.48% | 803,193 | SH |
| 3 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $50.4M | 5.90% | 1,574,698 | SH |
| 4 | UROGEN PHARMA LTD | URGN | M96088105 | $46.7M | 5.46% | 1,148,689 | SH |
| 5 | IMMUNOME INC | IMNM | 45257U108 | $45.0M | 5.27% | 2,092,715 | SH |
| 6 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $37.1M | 4.35% | 3,112,773 | SH |
| 7 | SAGIMET BIOSCIENCES INC | SGMT | 786700104 | $37.0M | 4.33% | 3,745,990 | SH |
| 8 | ASCENDIS PHARMA A/S | ASND | K08588103 | $34.7M | 4.06% | 152,175 | SH |
| 9 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $33.2M | 3.88% | 348,317 | SH |
| 10 | BIOGEN INC | BIIB | 09062X103 | $25.5M | 2.98% | 112,790 | SH |
| 11 | IMMUNOVANT INC | IMVT | 45258J102 | $21.1M | 2.47% | 624,055 | SH |
| 12 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $20.8M | 2.44% | 236,582 | SH |
| 13 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $20.6M | 2.42% | 247,918 | SH |
| 14 | ERASCA INC | ERAS | 29479A108 | $19.5M | 2.28% | 1,330,455 | SH |
| 15 | ABIVAX SA | ABVX | 00370M103 | $17.4M | 2.04% | 175,699 | SH |
| 16 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $15.8M | 1.85% | 487,589 | SH |
| 17 | OVID THERAPEUTICS INC | OVID | 690469101 | $14.8M | 1.73% | 5,950,000 | SH |
| 18 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $13.5M | 1.57% | 151,151 | SH |
| 19 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $13.2M | 1.54% | 345,946 | SH |
| 20 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $12.8M | 1.50% | 1,208,030 | SH |
| 21 | ALKERMES PLC | ALKS | G01767105 | $12.2M | 1.42% | 300,427 | SH |
| 22 | CELLDEX THERAPEUTICS INC NEW Call | CLDX | 15117B902 | $12.0M | 1.41% | 370,700 | SH |
| 23 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $11.5M | 1.35% | 3,454,647 | SH |
| 24 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $10.8M | 1.26% | 378,352 | SH |
| 25 | ORIC PHARMACEUTICALS INC Call | ORIC | 68622P909 | $9.5M | 1.11% | 702,400 | SH |
| 26 | CERUS CORP | CERS | 157085101 | $9.4M | 1.10% | 3,950,595 | SH |
| 27 | ALX ONCOLOGY HLDGS INC | ALXO | 00166B105 | $9.1M | 1.07% | 6,565,960 | SH |
| 28 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $9.0M | 1.05% | 334,057 | SH |
| 29 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $8.9M | 1.04% | 717,356 | SH |
| 30 | RAINIER ACQUISITION CORP | RNAQU | G73591110 | $8.7M | 1.02% | 853,875 | SH |
| 31 | COMPUGEN LTD | CGEN | M25722105 | $8.5M | 1.00% | 3,586,785 | SH |
| 32 | SAVARA INC | SVRA | 805111101 | $7.8M | 0.92% | 1,518,833 | SH |
| 33 | VAXCYTE INC | PCVX | 92243G108 | $7.1M | 0.83% | 125,080 | SH |
| 34 | YARROW BIOSCIENCE INC | YARW | 92941V407 | $6.8M | 0.80% | 301,919 | SH |
| 35 | IBIO INC | IBIO | 451033708 | $6.3M | 0.74% | 5,357,088 | SH |
| 36 | ARCTURUS THERAPEUTICS HLDGS | ARCT | 03969T109 | $6.3M | 0.74% | 459,899 | SH |
| 37 | MONTE ROSA THERAPEUTICS INC Call | GLUE | 61225M902 | $6.3M | 0.73% | 525,000 | SH |
| 38 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $5.8M | 0.67% | 19,753 | SH |
| 39 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $5.6M | 0.66% | 75,697 | SH |
| 40 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $5.6M | 0.65% | 121,452 | SH |
| 41 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $5.5M | 0.64% | 760,337 | SH |
| 42 | EVOMMUNE INC | EVMN | 30054Y107 | $4.9M | 0.57% | 594,027 | SH |
| 43 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $4.7M | 0.54% | 247,418 | SH |
| 44 | BENITEC BIOPHARMA INC | BNTC | 08205P209 | $4.4M | 0.52% | 443,109 | SH |
| 45 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $4.4M | 0.51% | 404,728 | SH |
| 46 | BLOSSOMHILL THERAPEUTICS INC | BLSM | 095130100 | $3.8M | 0.44% | 202,104 | SH |
| 47 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $3.7M | 0.43% | 124,098 | SH |
| 48 | ABEONA THERAPEUTICS INC | ABEO | 00289Y206 | $3.6M | 0.43% | 693,441 | SH |
| 49 | RESEARCH ALLIANCE CORP IV | RACD | G75228109 | $3.5M | 0.41% | 301,962 | SH |
| 50 | ADLAI NORTYE GROUP LTD | ANL | 00704R109 | $3.5M | 0.41% | 216,617 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-12 | $854.4M | 70 | 0001420506-26-002577 |
| 2026-06-30 | 2026-08-13 | $962.2M | 73 | 0001420506-26-001563 |
| 2026-03-31 | 2026-05-14 | $979.8M | 73 | 0001420506-26-001011 |
| 2025-12-31 | 2026-02-12 | $720.1M | 68 | 0001420506-26-000321 |
| 2025-09-30 | 2025-11-12 | $741.6M | 82 | 0001420506-25-003142 |
SUITE 620
BOSTON, MA 02116